next generation AUTO-3 program (Autolus)

N/A

Report date: 2025/03/20 15:11:40

Base Information

Drug Namenext generation AUTO-3 program (Autolus)

Drug Alias NameAUTO-3 NGnext generation dual anti-CD19/anti-CD22 CAR T-cell therapy (Autolus)

ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionCD22 modulatorsB-lymphocyte antigen CD19 modulators

TargetsCD22B-lymphocyte antigen CD19

Therapy Area/IndicationsLymphoma, Non-HodgkinPrecursor Cell Lymphoblastic Leukemia-LymphomaNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited Kingdom

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesAutolus Therapeutics Plc

China Registration ClassN/A

Develop Information

Active CompaniesAutolus Therapeutics Plc

Inactive CompaniesN/A

Active IndicationsLymphoma, Non-HodgkinPrecursor Cell Lymphoblastic Leukemia-Lymphoma

Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A